SCHEDULE: PRIMECAP Boosts BioMarin Stake to 8.24%
Institutional Ownership Disclosure
PRIMECAP MANAGEMENT CO/CA/ has increased its beneficial ownership in BioMarin Pharmaceutical Inc. to 8.24% of the common stock.
Summary
- PRIMECAP MANAGEMENT CO/CA/ reported beneficial ownership of 15,795,383 shares of BioMarin Pharmaceutical Inc. common stock.
- This represents 8.24% of the total class of securities.
- PRIMECAP MANAGEMENT CO/CA/ holds sole voting power over 15,087,400 shares.
- PRIMECAP MANAGEMENT CO/CA/ holds sole dispositive power over 15,795,383 shares.
- The filing is an Amendment No. 25 to Schedule 13G, filed under Rule 13d-1(b) as an investment adviser.
- The event date requiring this filing was June 30, 2025.
Sentiment
Score: 7
Explanation: The filing indicates a significant and continued institutional investment by PRIMECAP MANAGEMENT CO/CA/ in BioMarin Pharmaceutical Inc., which is generally viewed positively as a sign of investor confidence. However, it is a routine ownership disclosure and does not contain new operational or financial performance data.
Positives
- PRIMECAP MANAGEMENT CO/CA/, a significant institutional investor, maintains a substantial 8.24% stake in BioMarin Pharmaceutical Inc., indicating continued confidence in the company.
Negatives
- No negative information is disclosed in this Schedule 13G filing.
Risks
- This Schedule 13G filing does not disclose specific risks related to BioMarin Pharmaceutical Inc.'s operations or financial health.
Future Outlook
This Schedule 13G filing does not contain forward-looking statements or guidance.
Industry Context
This filing indicates a significant institutional investment in BioMarin Pharmaceutical Inc., a company operating in the biotechnology and pharmaceutical sector, reflecting ongoing investor interest in the industry.
Comparison to Industry Standards
- This Schedule 13G filing does not provide data for direct comparison to industry standards or specific comparable companies.
Stakeholder Impact
- Shareholders: Provides transparency on significant institutional ownership, potentially influencing investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring filing of this statement |
| 08/13/2025 | Signature date of the filing |
Keywords
BioMarin Pharmaceutical, PRIMECAP MANAGEMENT, SEC Filing, Schedule 13G, Institutional Ownership, Biotech, Pharmaceutical, Investment, Common Stock, 09061G101
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.